 Drug Resistance
"Drug Resistance" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.
| Descriptor ID |
D004351
|
| MeSH Number(s) |
G07.690.773.984
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance".
This graph shows the total number of publications written about "Drug Resistance" by people in this website by year, and whether "Drug Resistance" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 0 | 3 | 3 | | 1998 | 0 | 1 | 1 | | 1999 | 0 | 6 | 6 | | 2000 | 0 | 2 | 2 | | 2001 | 0 | 2 | 2 | | 2002 | 0 | 3 | 3 | | 2003 | 0 | 3 | 3 | | 2004 | 0 | 4 | 4 | | 2005 | 0 | 5 | 5 | | 2006 | 0 | 2 | 2 | | 2007 | 3 | 1 | 4 | | 2008 | 1 | 1 | 2 | | 2009 | 1 | 1 | 2 | | 2010 | 1 | 4 | 5 | | 2011 | 2 | 2 | 4 | | 2012 | 1 | 6 | 7 | | 2013 | 3 | 2 | 5 | | 2014 | 2 | 0 | 2 | | 2015 | 2 | 1 | 3 | | 2016 | 1 | 2 | 3 | | 2017 | 4 | 3 | 7 | | 2018 | 3 | 2 | 5 | | 2019 | 3 | 3 | 6 | | 2020 | 2 | 1 | 3 | | 2021 | 0 | 1 | 1 | | 2022 | 1 | 2 | 3 | | 2025 | 2 | 0 | 2 | | 2026 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Resistance" by people in Profiles.
-
Sanuade OA, Addo DK, Smith JD, Carroll AJ, Shimbo D, Talegawkar S, Tucker KL, Jacobs JA, Derington CG, Bress AP. The association of urinary sodium with incident apparent treatment resistant hypertension among African Americans: findings from the Jackson Heart Study. J Hum Hypertens. 2026 May; 40(5):405-412.
-
Bhamidipati K, McIntyre ABR, Kazerounian S, Ce G, Wong SW, Tran M, Prell SA, Lau R, Khedgikar V, Altmann C, Small A, Madhu R, Presti SR, Anufrieva KS, Blazar PE, Lange JK, Seifert JA, Moreland LW, Croft AP, Smith MH, Donlin LT, Lewis MJ, Jonsson AH, Pitzalis C, Thomas R, Gravallese EM, Brenner MB, Korsunsky I, Wechalekar MD, Wei K. Spatial patterning of fibroblast TGFß signaling underlies treatment resistance in rheumatoid arthritis. Nat Immunol. 2026 Mar; 27(3):556-571.
-
Mazigo E, Jun H, Lee WJ, Louis JM, Syahada JH, Fitriana F, Muh F, Ahmed MA, Lu F, Han JH, Kwon TH, Lee SJ, Na S, Chun W, Park WS, Han ET, Kidima W, Han JH. Emergence of chloroquine-sensitive Plasmodium falciparum and rising resistance to first-line artemisinin partner drugs in Malawi. Emerg Microbes Infect. 2025 Dec; 14(1):2572679.
-
Patel S, Lyberger K, Vegvari C, Gulbudak H. Eco-evolutionary dynamics of anthelmintic resistance in soil-transmitted helminths. Theor Popul Biol. 2025 Jun; 163:80-90.
-
Choi HY, Torkko KC, Lucia MS, Mozhui K, Choi WY, Clark PE, Fowke JH. Change in prostate tissue gene expression following finasteride or doxazosin administration in the medical therapy for prostatic symptoms (MTOPS) study. Sci Rep. 2024 08 19; 14(1):19164.
-
Patel RC, Oyaro P, Thomas KK, Wagude J, Mukui I, Brown E, Hassan SA, Kinywa E, Oluoch F, Odhiambo F, Oyaro B, Kingwara L, Karauki E, Yongo N, Otieno L, John-Stewart GC, Abuogi LL. Point-of-care HIV viral load and targeted drug resistance mutation testing versus standard care for Kenyan children on antiretroviral therapy (Opt4Kids): an open-label, randomised controlled trial. Lancet Child Adolesc Health. 2022 10; 6(10):681-691.
-
Patel AG, Chen X, Huang X, Clay MR, Komorova N, Krasin MJ, Pappo A, Tillman H, Orr BA, McEvoy J, Gordon B, Blankenship K, Reilly C, Zhou X, Norrie JL, Karlstrom A, Yu J, Wodarz D, Stewart E, Dyer MA. The myogenesis program drives clonal selection and drug resistance in rhabdomyosarcoma. Dev Cell. 2022 05 23; 57(10):1226-1240.e8.
-
Bertol BC, Bales ES, Calhoun JD, Mayberry A, Ledezma ML, Sams SB, Orlicky DJ, Donadi EA, Haugen BR, French JD. Lenvatinib Plus Anti-PD-1 Combination Therapy for Advanced Cancers: Defining Mechanisms of Resistance in an Inducible Transgenic Model of Thyroid Cancer. Thyroid. 2022 02; 32(2):153-163.
-
Martinez M, Perito ER, Valentino P, Mack CL, Aumar M, Broderick A, Draijer LG, Fagundes EDT, Furuya KN, Gupta N, Horslen S, Jonas MM, Kamath BM, Kerkar N, Kim KM, Kolho KL, Koot BGP, Laborda TJ, Lee CK, Loomes KM, Miloh T, Mogul D, Mohammed S, Ovchinsky N, Rao G, Ricciuto A, Rodrigues Ferreira A, Schwarz KB, Smolka V, Tanaka A, Tessier MEM, Venkat VL, Vitola BE, Woynarowski M, Zerofsky M, Deneau MR. Recurrence of Primary Sclerosing Cholangitis After Liver Transplant in Children: An International Observational Study. Hepatology. 2021 10; 74(4):2047-2057.
-
Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA, Gaur AH, Gonzales P, Tran HV, Hinojosa JC, Kallas EG, Kelley CF, Losso MH, Madruga JV, Middelkoop K, Phanuphak N, Santos B, Sued O, Valencia Huamaní J, Overton ET, Swaminathan S, Del Rio C, Gulick RM, Richardson P, Sullivan P, Piwowar-Manning E, Marzinke M, Hendrix C, Li M, Wang Z, Marrazzo J, Daar E, Asmelash A, Brown TT, Anderson P, Eshleman SH, Bryan M, Blanchette C, Lucas J, Psaros C, Safren S, Sugarman J, Scott H, Eron JJ, Fields SD, Sista ND, Gomez-Feliciano K, Jennings A, Kofron RM, Holtz TH, Shin K, Rooney JF, Smith KY, Spreen W, Margolis D, Rinehart A, Adeyeye A, Cohen MS, McCauley M, Grinsztejn B. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021 08 12; 385(7):595-608.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|